SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending after a short-seller released a report alleging substantial financial overstatements and undisclosed related-party transactions, raising serious questions about the company's accounting practices. This has sparked intense community debate over its fundamental health, market manipulation, and the credibility of analyst ratings, with many drawing parallels to past major fraud accusations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is surging to unprecedented new highs, fueled by broad market concerns over dollar debasement, inflation, and geopolitical instability, leading many to declare it the ultimate "safe play" and the "death of fiat." However, this rapid, "parabolic" ascent is also sparking intense debate, with some community members calling it "bubble territory" and aggressively shorting the perceived mania.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending due to recent analyst downgrades, intensifying an already negative market sentiment ahead of its crucial earnings report. The community is sharply divided, with bears citing a value trap and stiff competition, while bulls point to deep undervaluation, aggressive share buybacks, and new AI/partnership initiatives as catalysts for an imminent rebound. Investors are keenly watching for signs of fundamental strength to counter ongoing market skepticism.

Namib Minerals is a gold producer, developer and explorer with operations focused in Zimbabwe. The company was founded on June 5, 2025 and is headquartered in George Town, Cayman Islands.

Namib Minerals.

Namib Minerals

Namib Minerals (NAMM) is trending amidst soaring gold prices reaching all-time highs, igniting strong community interest. Discussions frequently revolve around a potential short squeeze, with many anticipating substantial price appreciation and actively watching for key resistance levels to break, driven by the stock's low float and high cost-to-borrow for shorts.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is generating significant buzz ahead of its anticipated earnings report, with investors sharply divided on whether the company's aggressive AI infrastructure spending will drive strong returns or disappoint. The community is actively debating the impact of these substantial investments and the potential for a volatile market reaction. This report is keenly watched as a key indicator for the broader tech sector, especially concerning AI development and capital expenditures.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is heavily trending as investors anticipate its upcoming earnings report, with community sentiment sharply divided and many expressing extreme frustration over the stock's recent price action. Despite a history of strong financial performance and expectations for another beat, shareholders are vocal about perceived market manipulation and the impact of a recent stock offering, while long-term holders view current levels as a significant buying opportunity ahead of potential S&P 500 inclusion and future growth.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amidst high anticipation for upcoming clinical data presentations at a Glioblastoma scientific summit and recent Saudi FDA approval for a lung cancer therapy. The community is actively discussing the stock's significant short interest, anticipating potential short squeeze dynamics, and expressing strong conviction in the company's innovative 'BioShield' platform to deliver groundbreaking cancer treatments.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending after announcing a $75 million registered direct offering to a single institutional investor, intended to fund preparations for its upcoming Phase 3 MASH trial, which triggered significant pre-market volatility. The community is sharply divided, with some viewing the financing as a strategic de-risking move that bolsters confidence in the company's best-in-class pemvidutide, while others express frustration over dilution and a perceived lack of immediate partnership. Despite initial share price reactions, optimists highlight the institutional backing and a recent analyst $20 price target as validation for Altimmune's potential in the high-value MASH market.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as the market grapples with the Federal Reserve's decision to hold interest rates, with many community members labeling the outcome and Jerome Powell's press conference a "nothing burger" due to limited immediate price movement. This has led to frustration among options traders, as participants now keenly await upcoming big tech earnings for the next significant market catalyst amidst mixed signals on economic strength and inflation.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending after announcing a U.S. Air Force contract to advance multi-domain swarming capabilities using its SwarmOS AI platform, extending its technology to integrate satellite operations. The community is actively debating the significance of this development, with many optimistic about its implications for defense AI and robotics, while others express caution due to the undisclosed contract value and historical market reactions to similar news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Joseph Oliveto Sells 43,000 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 43,000 shares of the firm's stock in a transaction dated Thursday, January 8th. The stock was sold at an average...

Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday...

Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 186.2% in the 3rd quarter, according to the company in its most recent...

Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat reports...

Aptars Bidose Nasal System Delivers CARDAMYST (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the...

What is HC Wainwright's Estimate for MIST FY2026 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a report...

Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 4,480 call options on the company. This is an...

<ul class="summary-bullets"><li>Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia and restore sinus rhythm.</li><li>The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.</li><li>Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter of 2026.</li></ul>Shares of Milestone Pharmaceuticals Inc. (MIST) rose nearly 32% in Monday’s pre-market after the company received approval from the U.S. Food and Drug Administration (FDA) for its first commercial product late Friday.Milestone announced that the FDA approved Cardamyst, a novel nasal spray designed to rapidly resolve episodes of Paroxysmal Supraventricular Tachycardia (PSVT) and restore sinus rhythm.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MIST">Milestone stock</a> trended in the ‘extremely bullish’ territory, while message volumes were at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Cardamyst Approval</h2>Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT. The nasal spray can be self-administered by patients outside the emergency department or other healthcare settings, the company said.Milestone expects Cardamyst to be available for purchase at retail pharmacies in the first quarter (Q1) of 2026.“Cardamyst is a novel at-the-ready treatment option that addresses the unpredictable impact of PSVT by offering patients the freedom to manage episodes anytime and anywhere,” said Joseph Oliveto, CEO, Milestone Pharmaceuticals.<h2 class="st-heading-2">Clinical Data</h2>Milestone stated that Cardamyst’s approval by the FDA is based on safety data from more than 1,800 participants and over 2,000 episodes of PSVT.The company said that participants using Cardamyst were twice as likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster than with a placebo.<h2 class="st-heading-2">Retail Optimistic</h2>Retail users on Stocktwits expressed their optimism around the company and Cardamyst following the FDA approval.One user said that the most challenging part for the company was over after the approval, adding that those who are long on the stock have “ZERO to worry about here.”<stembedurl>https://stocktwits.com/Wut_About_Bob/message/639158529</stembedurl>Another user dismissed concerns that this is a “sell the news” event, adding that they are “waiting with 0 worries.”<stembedurl>https://stocktwits.com/MarketILF/message/639154331</stembedurl><a href="https://stocktwits.com/symbol/MIST">MIST stock</a> is up 2% year-to-date and 30% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-fully-priced-for-autonomy-ev-demand-weakens-gary-black/cLeECtqRE8s">Is TSLA Stock Fully Priced For Autonomy? Here's What Gary Black Thinks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

Equity

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.16	--	--	N/A
Q3 '25	-$0.16	-$0.12	26.83%	BEAT
Q2 '25	-$0.18	-$0.20	-12.68%	MISSED
Q1 '25	-$0.19	-$0.31	-67.57%	MISSED
Q4 '24	-$0.16	-$0.19	-21.79%	MISSED

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest MIST News

MISTMilestone Pharmaceuticals Inc